SI-BONE Third Quarter 2026 Earnings Call - SI-BONE INC

Financial Performance:

• Worldwide revenue grew 14.5% YoY to $55.7 million, driven by 20% procedure volume growth; U.S. revenue reached $52.8 million (+13.9%), while International revenue grew 27% to $2.9 million.
• Adjusted EBITDA surged 32.4% to $2.3 million (5.5% margin), representing a 140% increase over the trailing twelve months to nearly $13.6 million.
• Gross margin held steady at 79.3%, exceeding guidance due to production workflow optimizations and improved capacity utilization, despite mix shifts toward lower-ASP sites of care.
• Net loss narrowed to $3.6 million ($0.08/share) from $4.6 million ($0.11/share) YoY.
• Operating cash flow improved significantly to $4.4 million YTD vs. $2.4 million used in the prior year period, with cash and equivalents rising to $146.3 million.
• Operating expenses grew only 9.7%, well below revenue growth, indicating strong operating leverage.

Guidance and Future Outlook:

• Reaffirmed 2026 full-year worldwide revenue guidance of $231–$233 million and gross margin of 79%.
• Lowered 2026 operating expense growth guidance to 10.5% (previously 12%) to reflect disciplined spending.
• Q4 2026 midpoint guidance implies >20% YoY revenue growth, driven by seasonality, Onyx launch, and interventional platform expansion.
• Management expects accelerating growth into 2027 and 2028, targeting consistent long-term operating leverage of 1.25x to 1.75x revenue-to-OPEX growth.
• Long-term gross margin expectations may moderate to ~78% post-2027 due to depreciation on new surgical capacity, though remaining industry-leading.
• Anticipates 2027 profitability improvement through volume ramp and ASP upside from new products and reimbursement changes.

Business Segments and Product Lines:

• Onyx Platform: Launched FDA-cleared "Onyx" in October (alpha phase); targets UIV/LIV screw loosening in complex spinal fusion. Estimated market size of $1.5B U.S. ($200k procedures), bringing total complex fusion TAM to $2.5B; combined with Granite, TAM exceeds $650k procedures ($5B opportunity).
• Granite Platform: Maintains standard of care for sacropelvic fixation; new DRGs effective Oct 1, 2026, could increase hospital payments by up to $50k per case.
• Intra Platform: Gaining traction with interventional spine physicians in ASC and office-based settings, driving volume growth despite lower ASPs.
• Trauma Segment: Collaboration with Smith & Nephew on TNT and TORC platforms showing early adoption momentum entering trauma season.
• Physician Base: Active physicians grew 16% YoY to ~1,770; territory count at 93, targeting nearly 100 by year-end.

Market and Competitive Landscape:

• Market focus on high-risk patients with compromised bone quality (osteoporosis/osteopenia) creates a $650,000+ annual procedure opportunity.
• Onyx addresses a known failure point (27% screw loosening rate) with no direct good alternatives, positioning SI Bone as a unique provider for complex fusions.
• Competitive advantage derived from anatomy-specific solutions and a broad footprint covering surgeons and interventionalists across all sites of care.
• Reimbursement tailwinds include new DRGs for Granite (Oct 1, 2026) and potential NTAP approval for Onyx (potential effective date Oct 1, 2027).
• Proposed CMS changes for SI joint dysfunction could raise ASC payments to >$16k and office payments to $20k, effective potentially Jan 1, 2027.

Risks and Challenges:

• Potential modest gross margin pressure in 2027+ due to higher non-cash depreciation expenses from deploying Onyx surgical capacity.
• ASP volatility risks from procedure mix shifts (growth in lower-ASP interventional settings vs. higher-ASP complex fusion).
• Dependence on regulatory approvals, specifically CMS finalization of proposed site-of-care reimbursement changes.
• Commercial execution risk in scaling surgical capacity and training physicians for the full Onyx launch in January.
• Macro industry procedure volume slowdowns remain a general risk, though management sees resilience due to addressing unmet clinical needs.

Management Commentary and Tone:

• Tone is highly confident and optimistic, citing a "defining moment" driven by product innovation, reimbursement enhancements, and commercial scale.
• Management emphasized "disciplined execution" and "operating leverage," noting the ability to grow revenue significantly faster than operating expenses.
• Leadership expressed strong belief in the "halo effect" where existing Granite adoption accelerates Onyx uptake and vice versa.
• Emphasis on the strategic shift toward "anatomy-specific solutions" for compromised bone as a difficult-to-replicate competitive moat.

Analyst Questions and Answers:

• Onyx Adoption: Clarified that early alpha launch shows strong demand, with existing Granite users adding Onyx (up to 6 implants/case) and new users adopting it for non-pelvic cases; early trends track ahead of Granite's initial launch.
• 2027 Guidance: Management declined to provide specific 2027 revenue guidance, citing the need to close 2026 strong and complete planning, but expressed confidence in growth acceleration driven by Onyx, DRGs, and interventional growth.
• Profitability Trajectory: Confirmed commitment to 1.25x–1.75x OPEX-to-Revenue leverage; expects significant bottom-line improvement as top-line growth accelerates despite growth-oriented R&D and sales force investments.
• ASP Trends: Expect net ASP improvement in H2 2026 and 2027 as Onyx adoption (higher implant count) offsets lower-ASP interventional mix, aided by new DRGs.
• Smith & Nephew Partnership: Noted the partnership is maturing with results starting to appear as they enter the busy trauma season, though longer onboarding times are expected compared to internal launches.
• Clinical Data for Onyx: Stated reliance on bench/animal data initially, with a prospective multi-center study planned; early adopters are proceeding without 12–24 month clinical outcomes due to lack of good alternatives.

Other Key Points:

• Onyx received its third FDA Breakthrough Device designation.
• NTAP application for Onyx submitted; decision expected Oct 1, 2027.
• The company converted its "asset-light" operating model into stronger cash generation, with working capital discipline aiding free cash flow.
• The "Granite" platform is now considered the standard of care in sacropelvic fixation following four years of clinical success and studies (PAULA, Sylvia).
• Management highlighted the "hybrid" sales model (direct reps + third-party agents) as a key driver for scaling territory coverage efficiently.